Oddo BHF - BioNTech SE (BNTX) BioNTech SE : T3 2024 au-dessus des attentes. Guidance 2024 ajustée

Report

Oddo BHF

Damien Choplain ...

Martial Descoutures

BioNTech SE : T3 2024 au-dessus des attentes. Guidance 2024 ajustée

>Topline positivement impactée par un phasing avantageux des approbations des vaccins COVID-19 - BioNtech publie un CA T3 au-dessus des attentes au niveau du CA (+183%) et du BPA (0.8 € vs css -1.5 €). Le CA s'établit à 1 244 M€ au T3 (39% YoY) et à 1 560 M€ sur 9M (-33% YoY). Cette bonne performance sur le T3 est principalement liée aux approbations reçues plus tôt pour ses nouveaux vaccins COVID-19 vs 2023. Les coûts de R&D progressent de 11% à 550 M€, 15% en dess...

05/11/2024 1 FR

Underlying

BioNTech SE

See profile

US09075V1026 NASDAQ Stock Market Germany

Provider

Oddo BHF

Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

See profile

Analysts

Damien Choplain

Martial Descoutures

Other Reports on these Companies

Oddo BHF

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 11/05/2024

European equity markets weakened in October following multiple disappointments across the earnings season. The impending US election, the outcome of which is highly uncertain according to the polls, may also have prompted some traders to adopt a cautious stance. Sovereign long rates rose sharply, particularly in the US, on the back of macro indicators likely to provide arguments to the most hawkish of central bankers. All eyes are now on the November 5 elections and their repercussion...

November 5, 2024 November 5, 2024 1 EN

Oddo BHF

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 05/11/2024

Les marchés actions européens ont fléchi en octobre après les nombreuses déceptions sur la saison des résultats. L’approche de l’élection US, très incertaine selon les sondages, pourrait également avoir poussé à la prudence certains opérateurs. Les taux longs souverains ont nettement remonté, en particulier aux Etats-Unis, sur la base d’indicateurs macro susceptibles de donner des arguments aux plus faucons des banquiers centraux. Tous les yeux sont désormais rivés sur le scrutin du 5...

November 5, 2024 November 5, 2024 1 FR

Oddo BHF

BioNTech SE : Q3 exceeds expectations. 2024 guidance adjusted

>Top line positively impacted by advantageous phasing of COVID 19 vaccine approvals - BioNtech reported Q3 figures that beat expectations at the level of sales (+183%) and EPS (€ 0.8 vs consensus -€ 1.5). Sales amounted to € 1,244m in Q3 (39% y-o-y), bringing sales in the first 9 months to € 1,560m (-33% y-o-y). This good performance in Q3 mainly reflected the approvals received earlier for its new COVID 19 vaccines vs 2023. R&D costs rose 11% to € 550m, 15% below th...

November 5, 2024 November 5, 2024 1 EN

CaixaBank : Medium-term strategic update: underpinning win/win profile in the rate cycle

We maintain our Outperform rating on CaixaBank, one of our Top Picks in the sector, with a higher target of € 7.2 vs € 6.7 and ahead of the CMD on 19 November. We are lifting our net income estimates by 7% for 2025-2026, to 7% above the consensus. The strategic update is set to highlight the wisdom of the business model diversification (long-term savings) to address the current transition phase on rates. Despite a solid market performance, the profile does not look to be fully r...

8h / 26m 8h / 26m 1 EN

Benoit Valleaux ... (+2)

Benoit Valleaux
Steven Gould

CaixaBank : Update stratégique MT : conforter le profil ‘win/win’ face au cycle de taux

Nous réitérons notre opinion Surperformance sur CaixaBank, l’un de nos top picks du secteur, avec un OC porté à 7.2 € vs 6.7 € et en amont du CMD du 19/11. Nous relevons nos anticipations de RN de 7% sur 2025/2026 qui ressortent 7% supérieures au consensus. L’update stratégique devrait mettre en avant la pertinence de la diversification du business model (épargne LT) face à la transition actuelle sur les taux. Malgré un solide parcours boursier, cela n’est pas pleinement reflété ...

8h / 32m 8h / 32m 1 FR

Farid Bitari ... (+2)

Farid Bitari
Nicolas David

Temenos : Midterm financial targets significantly cut but still above expectations. Short term investments announced

>New market growth outlook of c.7% by 2028 (vs 10% prev) and new midterm financial targets - Temenos this morning released a new market growth outlook and new mid-term financial targets above expectations. The group now sees market growth with a 2024-2028 CAGR of c.7%, 1pct point above our expectations (at 6%) but 3pct point below the previous outlook of 10%. This trend will be driven by double-digit growth in Public Cloud and SaaS, implying low growth in the On-premi...

14h / 26m 14h / 26m 1 FR

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

BioNTech SE : T3 2024 au-dessus des attentes. Guidance 2024 ajustée

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 11/05/2024

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 05/11/2024

BioNTech SE : Q3 exceeds expectations. 2024 guidance adjusted

CaixaBank : Medium-term strategic update: underpinning win/win profile in the rate cycle

CaixaBank : Update stratégique MT : conforter le profil ‘win/win’ face au cycle de taux

Temenos : Midterm financial targets significantly cut but still above expectations. Short term investments announced

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe